Telix is a title partner of the 52nd Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting (ASM) being held this week in Brisbane, Queensland, 13-15 May.
2nd Joint Telix and Duchembio Symposium – Clinical Utility of PSMA PET Imaging in Prostate Cancer and Key PSMA PET Image Interpretation for Urologists
On World Theranostics Day, with our partner, Duchembio, we are pleased to present the 2nd joint symposium on the clinical utility of PSMA-PET in prostate cancer imaging and key PSMA PET image interpretation for urologists in Korea.
New Video Series “PSMA PET/CT TODAY” Discusses the Future of Prostate Cancer Care with Leading Experts
Telix is pleased to announce the launch of PSMA PET/CT Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in prostate cancer care.
TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021
Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosis) study of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab) in patients with Systemic Amyloid Light Chain Amyloidosis (AL-Amyloidosis), presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
ZIRCON Presentation at International Kidney Cancer Symposium 2021
Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron emission tomography (PET), presented at the International Kidney Cancer Symposium (IKCS) 2021, organized by the Kidney Cancer Association.
Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021
Telix is pleased to announce a satellite symposium at the 34th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held from 20-23 October 2021.
Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer
Telix is delighted to announce our support for the AdMeTech 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from 23-25 September 2021.